双膦酸盐类药物所致乳腺癌患者颌骨坏死：一项系统评价
Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review.
作者信息
Varun Br, Sivakumar Tt, Nair Bindu J, Joseph Anna P
机构信息
Department of Oral and Maxillofacial Pathology, PMS Institute of Dental Science and Research, Trivandrum, Kerala, India.
出版信息
J Oral Maxillofac Pathol. 2012 May;16(2):210-4. doi: 10.4103/0973-029X.98893.
BACKGROUND
Bisphosphonate therapy is widely used for the treatment of bone metastasis in breast cancer patients.
AIM
The aim of this study is to estimate the overall prevalence of bisphosphonate induced osteonecrosis of jaw (BONJ) in breast cancer patients with bone metastasis.
MATERIALS AND METHODS
A literature review was conducted to search and evaluate all the articles that contained original data on the prevalence of BONJ in breast cancer patients from the year 2003-2009. Pubmed search terms used were bisphosphonate, osteonecrosis, breast cancer and jaw. Eleven publications that fulfilled the inclusion criteria were chosen for the study. Case reports and reviews were excluded from the analysis based on assessing the title and abstract.
RESULTS
Of the 2490 breast cancer patients, 69 developed BONJ with the overall prevalence rate of 2.8%. All the patients with BONJ had received zoledronate or pamidronate, either alone or in combinations.
CONCLUSION
BONJ is a significant complication occurring in 2.8% of the breast cancer patients receiving bisphosphonates for metastatic bone disease. It is very important to identify the trigger factors associated with BONJ and also to establish guidelines for the prevention and effective treatment of this condition.
背景
双膦酸盐疗法广泛用于治疗乳腺癌患者的骨转移。
目的
本研究旨在评估双膦酸盐诱导的颌骨坏死（BONJ）在骨转移乳腺癌患者中的总体患病率。
材料与方法
进行文献综述，以检索和评估2003年至2009年间所有包含乳腺癌患者BONJ患病率原始数据的文章。在Pubmed中使用的检索词为双膦酸盐、骨坏死、乳腺癌和颌骨。选择了11篇符合纳入标准的出版物进行研究。根据标题和摘要评估，将病例报告和综述排除在分析之外。
结果
在2490例乳腺癌患者中，69例发生BONJ，总体患病率为2.8%。所有发生BONJ的患者均单独或联合接受过唑来膦酸或帕米膦酸治疗。
结论
BONJ是接受双膦酸盐治疗转移性骨病的乳腺癌患者中出现的一种严重并发症，发生率为2.8%。识别与BONJ相关的触发因素以及制定该疾病的预防和有效治疗指南非常重要。
Zotero 插件